Novo Nordisk A/S
Novo Nordisk A/S Q1 FY26 Results — Earnings Call Analysis
Q1 FY26 earnings call: what management said on revenue, margins and capex.
What the Q1 FY26 call signalled
1 of 3 strong
The short version
- 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges. - International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition. - U.S. - Novo Nordisk expects adjusted sales growth in 2026 to be between -5% to -13% at constant exchange rates, reflecting pricing headwinds, market dynamics, and competition. - Adjusted operating profit growth for 2026 is also projected in the range of -5% to -13% at constant exchange rates. - Reported growth in Danish kroner is expected to be about 3 percentage points (sales) and 5 percentage points (operating profit) lower than at constant exchange rates due to currency exchange effects. - Sales growth outlook factors in volume expansion in International Operations (mid-single-digit growth), offset by steep price declines and market competition in the U.S.
From Novo Nordisk A/S's Q1 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges.
- International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition.
- U.S. operations anticipate a significant sales decline in the teens, driven primarily by price reductions, competition, market access investments, and the impact of the Most Favored Nations (MFN) agreement.
- The global GLP-1 market is still expanding, with continued volume growth projected due to increased patient reach, particularly in obesity and diabetes care.
2 more points from Novo Nordisk A/S's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Novo Nordisk A/S said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure (CapEx) guidance for 2026 is expected to be around DKK 55 billion.
- CapEx investments are focused on manufacturing capacity expansion, including major API (active pharmaceutical ingredient) facilities.
- Novo Nordisk expects some new major API facilities to come online during 2026, with more expansions in subsequent years.
- Capital expenditure investments are anticipated to decline in the coming years following the finalization of expansion projects.
- Over DKK 60 billion was spent on manufacturing capacity expansion through CapEx in 2025.
- Novo Nordisk also allocates around DKK 30 billion towards expanding its R&D pipeline through business development.
2 more points from Novo Nordisk A/S's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Novo Nordisk A/S said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Novo Nordisk A/S said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Pharmaceuticals this season
- Haleon plc (Q1 FY26)
Haleon plc Q1 FY26 quarterly results analysis. Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. Marke
- Takeda Pharmaceutical Company Limited (Q1 FY26)
Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th
- Sanofi (Q1 FY26)
Sanofi Q1 FY26 quarterly results analysis. For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster tha
- Novartis AG (Q1 FY26)
Novartis AG Q1 FY26 quarterly results analysis. Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competiti
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Novo Nordisk A/S and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Novo Nordisk A/S Q1 FY26 results?
- 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges. - International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition. - U.S. - Novo Nordisk expects adjusted sales growth in 2026 to be between -5% to -13% at constant exchange rates, reflecting pricing headwinds, market dynamics, and competition. - Adjusted operating profit growth for 2026 is also projected in the range of -5% to -13% at constant exchange rates. - Reported growth in Danish kroner is expected to be about 3 percentage points (sales) and 5 percentage points (operating profit) lower than at constant exchange rates due to currency exchange effects. - Sales growth outlook factors in volume expansion in International Operations (mid-single-digit growth), offset by steep price declines and market competition in the U.S.
What is Novo Nordisk A/S share price analysis?
Novo Nordisk A/S currently shows a neutral. The stock trades at a P/E of 10.4 with a market cap of $203,202. Investors should review the full earnings analysis for detailed insights.
Is Novo Nordisk A/S planning capital expenditure?
- Capital expenditure (CapEx) guidance for 2026 is expected to be around DKK 55 billion.
Keep Novo Nordisk A/S on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.